Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery
Authors not listed
Nemocnice Kolín · 2025
Abstract
The goal of this clinical trial is to learn which of the drugs bromfenac 0.09%, nepafenac 0.3% and diclofenac 0.1% has better efficacy in treatment and prevention of cystoid macular oedema after cataract surgery.
The main questions it aims to answer are:
Which of the drugs has better efficacy in macular oedema prevention? What medical problems do participants have when taking different drugs? Researchers will compare drugs to each other.
Participants will:
Take on of the drugs (randomized) as their treatment in preoperative and postoperative period.
Visit the clinic after the surgery on the first day, first week, in three weeks and in six weeks.
Undergo retina examination with OCT (optical coherence tomography), best vision, and fill in forms considering their quality of life.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2025). Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery. <em>Nemocnice Kolín</em>. https://clinicaltrials.gov/study/NCT07178639
Vancouver
Anonymous. Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery. Nemocnice Kolín. 2025.
BibTeX
@misc{anon2025Compar,
title = {Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery},
author = {Anonymous},
journal = {Nemocnice Kolín},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Wangjing Hospital, China Academy of Chinese Medical Sciences 2026
Open access · US-GOV
Huangjing Yangji Formula Combined With Resistance Training for Sarcopenia: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Peking University Third Hospital 2025
Open access · US-GOV
Therapeutic Effect of Vitamin C Supplementation in Patients With Ovarian Aging:a Multicenter, Double-blind, Randomized Controlled Trial
Vanderbilt University Medical Center 2026
Open access · US-GOV
Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)
Clinica Universidad de Navarra, Universidad de Navarra 2021
Open access · US-GOV
Study of the Efficacy of a New Nutritional Supplement, Compared with Placebo, in Promoting Active and Healthy Aging from the Age of 65
University of North Carolina, Chapel Hill 2025
Open access · US-GOV
Feasibility and Correlation of Functional Muscle Strength Tests and Objective Frailty Measures With Clinical Frailty Scale in Patients Undergoing Major Surgery
Creighton University 2025
Open access · US-GOV